EGFR and cancer: This suggests that targeting RCC1 might have potential in combinatory therapy with first-line anti-cancer drugs like EGFR inhibitors [41], mTOR inhibitors [42] and AR inhibitors [43], whose effectiveness are often compromised by increased cytoplasmic distribution of Skp2.